News

It’s Time for NIH to Uphold the Law, Once Again

“As then NIH Director Elias Zerhouni noted in 2004 while rejecting the first march in petition seeking to impose price controls on a successfully commercialized product: ‘… the extraordinary remedy of march-in rights is not an appropriate means of controlling prices.’ That was correct then and remains so today.”

/IPWatchdog /As discussed previously, the critics are in full howl now that their attempts to enact legislation controlling drug prices has failed once again. Specifically, a petition by Knowledge Ecology International (KEI) to the National Institutes of Health (NIH) asks it to march in under the Bayh-Dole Act to force licensing to additional parties of the prostate cancer drug Xtandi, because of its cost. They are applying unprecedented political pressure on Secretary Xavier Becerra at the Department of Health and Human Services (HHS) to misuse the march in provisions of the Bayh-Dole Act to accomplish this goal.

Nearly 100 distinguished organizations and individuals endorsed the following letter from the Bayh-Dole Coalition, which I lead, warning HHS not to take this disastrous misstep.

Here’s what we said:

Dear Secretary Becerra:

We are writing to urge the Department of Health and Human Services to once again reject the petition asking the federal government to grant march-in rights for the patents on Xtandi, a prostate cancer drug, because of its price.

Similar petitions were appropriately rejected several times in the Obama-Biden Administration for a simple reason: the Bayh-Dole Act does not sanction marching in because critics don’t like the price of a successfully commercialized product that partially arose from a federally funded invention.

The purpose of the Bayh-Dole Act was not to create a mechanism for the federal government to set prices on successfully commercialized products. Rather, its explicit and well-understood purpose is to incentivize the commercialization of technologies developed from federally funded inventions. To that end, the law has been tremendously successful.

The public-private sector collaboration bolstered by the Bayh-Dole Act has facilitated the creation of more than 480,000 inventions and 15,000 start-ups, while supporting nearly six million new jobs.  Before Bayh-Dole, not a single new drug had been developed from NIH-funded inventions when the government took patent rights away from their creators.  Since its enactment, approximately 300 new drugs and vaccines are now protecting public health world-wide.

To ensure that discoveries and technologies supported by federal research funding are made available to the public, the law empowered government agencies to “march-in” forcing the patent owner to issue additional licenses – but only under very limited circumstances.

As Senator Birch Bayh explained, march-in rights were primarily a response to the concern that, “some companies might want to license university technologies to suppress them because they could threaten existing products.”  The law specifies four conditions in which march-in may be appropriate.  Controlling prices is not among them.

Appropriately, the NIH has previously rejected all petitions to march-in based on concerns about the price of commercially available products.  As the agency correctly and consistently concluded, using march-in rights to involve the NIH in drug pricing is a clear misapplication of the law.

As the Department of Defense succinctly stated to previous petitioners when it joined HHS in rejecting their similar efforts:

Your letter and supporting material show that Xtandi® has achieved practical application as the DHHS and DOD understand that term. Your request does not disclose information suggesting that supplies of Xtandi® are running low or that health or safety needs are not being met by the manufacturer. In view of the above information, we decline to exercise the government’s march-in authorities or utilize the government’s license to the enzalutamide patents.

The law has not changed, nor have the facts of this case. Thus, the current petition should be similarly rejected.

The Bayh-Dole Act laid the groundwork for the unprecedented partnerships between your department and the private sector, including those that helped lead to the development of life-saving vaccines and therapies to fight COVID-19. Misusing the law as the critics are now urging in the pending march-in petition threatens these relationships, as the government would appropriately no longer be viewed as a trustworthy partner.

The Bayh-Dole Act’s purpose was to translate federally funded scientific research into real-world products that make lives better here and around the world. By that measure, it has been incredibly effective. It was never intended as a means for the government to impose arbitrary price controls on resulting products, as the NIH has concluded time and again. As then NIH Director Elias Zerhouni noted in 2004 while rejecting the first march in petition seeking to impose price controls on a successfully commercialized product: “… the extraordinary remedy of march-in rights is not an appropriate means of controlling prices.”  That was correct then and remains so today.

Thank you for your consideration.

Sincerely,

Joseph P. Allen, Executive Director, Bayh-Dole Coalition

Katherine Bayh, wife of the late Senator Birch Bayh

John Hamre, Ph.D., former Deputy Secretary, U.S. Department of Defense

Paul Michel, J.D., (retired), former Chief Judge, U.S. Court of Appeals for the Federal Circuit

Brian Darmody, J.D., CEO, Association of University Research Parks (AURP); former Associate Vice President of Research and Economic Development, University of Maryland, College Park

Niels Reimers, Founder and former Executive Director of the Office of Technology Licensing, Stanford University

Joy Goswami, Assistant Director of Technology Transfer & Corporate Partnerships, University of Delaware; Board Director, AUTM

Kelly Sexton, Ph.D., Associate Vice President for Research and Innovation Partnerships, University of Michigan

Fred Reinhart, Sr. Advisor for Technology Transfer, UMass Amherst; Past President, AUTM

Jon Soderstrom, Ph.D., former Managing Director of University Technology Commercialization and Faculty Innovation, Yale University; Past President, AUTM

John Preston, former Director of Technology Development, Massachusetts Institute of Technology (MIT)

Vinit Nijhawan, former Managing Director of the Office of Technology Development, Boston University

John Fraser, Past President, AUTM

David Winwood, Ph.D., Past President, AUTM

Jane Muir, Past President, AUTM

Arundeep Pradhan, President, APIO Innovation Transfer; Past President, AUTM

Lori Pressman, 2017 AUTM Bayh-Dole Award Recipient

Lou Berneman, EdD, Founding Partner, emeritus, Osage University Partners

Lawrence Udell, Founder and Chairman, Licensing Executives Society – Silicon Valley Chapter

Adam Mossoff, J.D., Professor of Law Antonin Scalia Law School, George Mason University; Board Member Center for Intellectual Property Understanding

Christopher M. Holman, Ph.D., Professor of Law, University of Missouri-Kansas City School of Law; Senior Scholar, Center for Intellectual Property x Innovation at the Antonin Scalia Law School, George Mason University

Erika Lietzan, J.D., William H. Pittman Professor of Law & Timothy J. Heinsz Professor of Law at the University of Missouri School of Law

Kevin Noonan, Ph.D., Adjunct Professor, University of Illinois Chicago Law School; Founding Author, Patent Docs

Mickie A. Piatt, J.D., Associate Professor of Law and Co-Director of the Program in Intellectual Property Law, Chicago-Kent College of Law; Board Member, Center for Intellectual Property Understanding

Kristen Osenga, J.D., Austin E. Owen Research Scholar & Professor of Law, University of Richmond School of Law

Russell Somma, Ph.D., President and Pharmacist, SommaTech; former Director, Novartis

Mary Somma, MS, Manager and Pharmacist, Johnson & Johnson

Gene Quinn, J.D., President & CEO, IPWatchdog, Inc.

Richard T. Miner, J.D., (retired), former V.P. and General Counsel, Momentum Technologies, Inc.

 

AUTM

Licensing Executives Society (USA and Canada), Inc.

Council on Governmental Relations (COGR)

Magee-Womens Research Institute & Foundation

Purdue Research Foundation

Wisconsin Alumni Research Foundation

Small Business & Entrepreneurship Council

The Information Technology and Innovation Foundation (ITIF)

Alliance of US Startups and Inventors for Jobs

Arizona Bioindustry Association, Inc. (AZBio)

Biocom California

BioCT

BioFlorida

BioForward Wisconsin

BioHealth Innovation

BioKansas

BioNJ

Biotechnology Innovation Organization (BIO)

BioUtah

California Life Sciences

Delaware Bio

Georgia Bio

Illinois Biotechnology Innovation Organization (iBIO)

Indiana Health Industry Forum

K2 Biotechnology Ventures

Life Sciences Pennsylvania

Maryland Technology Council

MassBio

MichBio

Montana BioScience Association

New Mexico Biotechnology & Biomedical Association

NewYorkBIO

North Carolina Biosciences Organization (NCBIO)

Oklahoma Bioscience Association (OKBio)

Oregon Bioscience Association

Pharmaceutical Research and Manufacturers of America (PhRMA)

SCBIO

South Dakota Biotech

Texas Healthcare and Bioscience Institute (THBI)

Virginia Bio

Conservatives for Property Rights

Eagle Forum Education & Legal Defense Fund

Taxpayers Protection Alliance

U.S. Chamber of Commerce

Center for a Free Economy

ELITE Strategic Services, LLC

ExploraMed Development, LLC

Incubate Coalition

cc:

Secretary Lloyd J. Austin III, Department of Defense

Acting Director Lawrence A. Tabak, National Institutes of Health

Read more here.

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by